Skip to main content Skip to main navigation menu Skip to site footer

Sequencing analysis of anti mullerian hormone in polycystic ovarian syndrome and primary ovarian insufficiency

  • Budi Ermanto ,
  • Fadilah ,
  • Anom Bowolaksono ,
  • Asmarinah ,
  • Tono Djuwantono ,
  • Aria Kekalih ,
  • Mila Maidarti ,
  • Wisnu Ananta Kusuma ,
  • Budi Wiweko ,


Link of Video Abstract:


Introduction: Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and is the main cause of ovulation disorders. Primary ovarian insufficiency (POI) is a clinical syndrome characterized by loss of ovarian activity before the age of 40 years. All of these disorders lead to the risk of infertility. Therefore, this study aims to assess the AMH gene sequence and the effect of SNP on AMH levels and function.

Method: This research was a cross-sectional study. The sample was divided into three groups such as PCOS, POI, and control. This study used ELISA and PCR examination methods. Research data were analyzed using IBM SPSS version 22. The statistical analyses used were the ANOVA, Kruskal-Wallis, chi-square, and Spearman tests. A significant p-value was ≤ 0.05.

Results: There were 31 research subjects, 8 POI subjects, 16 PCOS subjects, and 7 control subjects. Overall 30 mutations were found, with two mutations in the gene promoter and 28 mutations in the structure of the AMH gene. Five mutations in the AMH gene structure were missense mutations. 14 SNPs were found in the POI group and 15 SNPs in the PCOS group. There was a significant difference in AMH AMH gene promoter mutation frequency distribution between the POI and PCOS groups at the mutation point 19:g.2249146T>G (p=0.007). In contrast, the mutation point 19:g.2249158T>A was not significantly different (p=0.536). There was no significant correlation between the number of promoter mutations and AMH gene structure with AMH levels in the POI, PCOS and control groups.

Conclusion: There were mutations in the promoter and AMH gene structure of the POI, PCOS, and control groups which caused differences in base sequences. However, in this study, the differences in mutations were not significantly different.


  1. Committee Opinion No. 605. Obstetrics & Gynecology. 2014;124(1):193–7. Available from:
  2. ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction. 2016;31(5):926–37. Available from:
  3. Laven J. Primary Ovarian Insufficiency. Semin Reprod Med. 2016;34(04):230–4. Available from:
  4. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360(6):606–14. Available from:
  5. Fortuño C, Labarta E. Genetics of primary ovarian insufficiency: a review. J Assist Reprod Genet. 2014/09/18. 2014;31(12):1573–85. Available from:
  6. Victoria M, Labrosse J, Krief F, Cédrin-Durnerin I, Comtet M, Grynberg M. Anti Müllerian Hormone: More than a biomarker of female reproductive function. J Gynecol Obstet Hum Reprod. 2019;48(1):19–24. Available from:
  7. Rey R, Lukas-Croisier C, Lasala C, Bedecarrás P. AMH/MIS: what we know already about the gene, the protein and its regulation. Mol Cell Endocrinol. 2003;211(1–2):21–31. Available from:
  8. Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online. 2016;33(1):15–28. Available from:
  9. Kevenaar ME, Laven JSE, Fong SL, Uitterlinden AG, de Jong FH, Themmen APN, et al. A Functional Anti-Müllerian Hormone Gene Polymorphism Is Associated with Follicle Number and Androgen Levels in Polycystic Ovary Syndrome Patients. The Journal of Clinical Endocrinology & Metabolism. 2008;93(4):1310–6. Available from:
  10. Qi X, Pang Y, Qiao J. The role of anti-Müllerian hormone in the pathogenesis and pathophysiological characteristics of polycystic ovary syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2016;199:82–7. Available from:
  11. Kevenaar ME, Themmen APN, Laven JSE, Sonntag B, Fong SL, Uitterlinden AG, et al. Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Human Reproduction. 2007;22(6):1547–54. Available from:
  12. Alvaro Mercadal B, Imbert R, Demeestere I, Gervy C, De Leener A, Englert Y, et al. AMH mutations with reduced in vitro bioactivity are related to premature ovarian insufficiency. Human Reproduction. 2015;30(5):1196–202. Available from:
  13. Wiweko B, Maidarti M, Priangga MD, Shafira N, Fernando D, Sumapraja K, et al. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod Genet. 2014/08/14. 2014;31(10):1311–6. Available from:
  14. Voorhuis M, Broekmans FJ, Fauser BCJM, Onland-Moret NC, van der Schouw YT. Genes Involved in Initial Follicle Recruitment May Be Associated with Age at Menopause. The Journal of Clinical Endocrinology & Metabolism. 2011;96(3):E473–9. Available from:
  15. Weenen C. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10(2):77–83. Available from:
  16. van Rooij IAJ. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Human Reproduction. 2002;17(12):3065–71. Available from:
  17. Carlsson IB. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Human Reproduction. 2006;21(9):2223–7. Available from:
  18. Durlinger ALL, Kramer P, Karels B, de Jong FH, Uilenbroek JThJ, Grootegoed JA, et al. Control of Primordial Follicle Recruitment by Anti-Müllerian Hormone in the Mouse Ovary1. Endocrinology. 1999;140(12):5789–96. Available from:
  19. Rigon C, Andrisani A, Forzan M, D’Antona D, Bruson A, Cosmi E, et al. Association study of AMH and AMHRII polymorphisms with unexplained infertility. Fertil Steril. 2010;94(4):1244–8. Available from:

How to Cite

Ermanto, B., Fadilah, Bowolaksono, A. ., Asmarinah, Djuwantono, T. ., Kekalih, A. ., Maidarti, M. ., Kusuma, W. A. ., & Wiweko, B. . (2023). Sequencing analysis of anti mullerian hormone in polycystic ovarian syndrome and primary ovarian insufficiency. Bali Medical Journal, 12(2), 2058–2066.